 |
 |
PRESS RELEASE 12:10 PM EDT Friday - August 29, 2003 Aderis Pharma floats $75M IPO Boston Business Journal Aderis Pharmaceuticals Inc., a Hopkinton developer of drugs to treat central nervous system, cardiovascular and inflammatory conditions, this week notified regulators that it intends to raise $75 million in an initial stock offering. The 9-year-old company, which used the name Discovery Therapeutics until early 2002, is developing four drug candidates to treat six conditions, including Rotigotine CDS, which is in Phase III trials to treat Parkinson's disease and is in a Phase IIb testing to treat Restless Legs Syndrome. Other candidates are being developed or are in tests for treating chronic diabetic foot ulcers; as a compound to simulate the stress effects of exercise on the heart prior to tests for coronary heart disease; for treating foot ulcers brought on by diabetes; and in controlling heart rate when a heart chamber contracts erratically. As is typical in initial IPO filings, the company did not specify a date or a price for its offering. Aderis employs 21 people and has operations in Virginia in addition to its Hopkinton headquarters. Major stakeholders in Aderis include the Sanderling Group of Menlo Park, Calif., Alliance Technology Ventures of Alphretta, Ga., and Schwarz Pharma AG of Germany. The offering will be underwritten by Lehman Brothers Inc., CIBC World Markets Corp. and U.S. Bancorp Piper Jaffray Inc. SOURCE: Boston Business Journal - August 29, 2003 http://boston.bizjournals.com/boston/stories/2003/08/25/daily42.html * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn